AbbVie
ABBV (NYSE)
AbbVie employs an income-plus-growth strategy, supported by a diversified pharmaceutical pipeline that includes promising immunology drugs like Skyrizi and Rinvoq. With a solid dividend yield of 3.10% and impressive returns of 26.58% over the past year and 117.84% over five years, the company is well-positioned for long-term growth. Analysts maintain a median price target of $258, reflecting a cautious sentiment with recent ratings ranging from neutral to overweight.
Pros:
- Strong dividend yield
- Diverse pharmaceutical pipeline
Cons:
- Market competition
- Regulatory risks
AbbVie (ABBV) may be a suitable investment for those seeking a combination of income and growth, particularly due to its solid dividend yield and strong historical performance. However, potential investors should consider the mixed analyst sentiment and ensure alignment with their individual risk tolerance and investment goals.